Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SALE OF COMMON STOCK (Details Narrative)

SALE OF COMMON STOCK (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands							1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2020	Feb. 07, 2020	Nov. 14, 2019	Dec. 13, 2018	Dec. 11, 2018	Dec. 07, 2018	Feb. 28, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Proceeds from the exercise of warrants								$ 7,474	$ 70
Number of options granted								556,500
Number of shares issued, value								$ 1,895
Net proceeds								16,681	$ 3
Preferred stock deemed dividend								1,260
Warrant deemed dividend								451
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock								$ 1,260
Warrants from Feb 7 Financing [Member]
Number of exercised warrants								10,800,000
Exercise price (in dollars per share)								$ 0.57
Proceeds from the exercise of warrants								$ 6,200
Warrants from Nov 2019 Financing [Member]
Number of exercised warrants								2,300,000
Exercise price (in dollars per share)								$ 0.57
Proceeds from the exercise of warrants								$ 1,300
Warrant deemed dividend								$ 500
Series B Convertible Preferred Stock [Member]
Number of shares converted (in shares)							5,313
Series A Convertible Preferred Stock [Member]
Number of shares converted (in shares)									9,856
Issuance of Series A Convertible preferred stock and common stock warrants (in shares)										7,938
Shares issue upon conversion of preferred stock (shares)									281,610
Underwriting Agreement [Member] \| Alliance Global Partners [Member]
Sale of stock, price (in dollars per share)	$ 1.10						$ 1.10
Percentage of underwriting discount	7.00%	7.00%	7.00%
Underwriting discount	$ 1,100	$ 500	$ 600
Net proceeds	14,800	6,500	7,900
Offering expenses	$ 100	500	$ 500
Number of shares issued (in shares)	14,550,000
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock		$ 1,300
Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Class A Units [Member]
Sale of stock, price (in dollars per share)			$ 1.94
Issuance of common stock and common stock warrants (in shares)			547,420
Number of common shares per unit			1
Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Class B Units [Member]
Sale of stock, price (in dollars per share)			$ 1,000
Issuance of Series A Convertible preferred stock and common stock warrants (in shares)			7,938
Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Warrant [Member]
Exercise price (in dollars per share)			$ 1.94
Warrants expiration period			5 years
Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Warrant [Member] \| Class B Units [Member]
Number of warrants to purchase to common stock per unit			515.464
Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Common Warrants [Member]
Exercise price (in dollars per share)			$ 1.94
Value of securities traded to trigger exercise of warrants			$ 9,000
Warrants expiration period			12 months
Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Common Warrants [Member] \| Class B Units [Member]
Number of warrants to purchase to common stock per unit			257.732
Underwriting Agreement [Member] \| Alliance Global Partners Dawson James Securities Inc [Member] \| Over-Allotment Option [Member]
Underwriting discount				$ 100
Number of shares issued (in shares)				25,000
Net proceeds				$ 800
Underwriting discount per share (in dollars per share)				$ 2.40
Underwriting Agreement [Member] \| Alliance Global Partners Dawson James Securities Inc [Member] \| Class A Units [Member]
Sale of stock, price (in dollars per share)						$ 35.00
Issuance of common stock and common stock warrants (in shares)						86,171
Number of common shares per unit						1
Number of warrants to purchase to common stock per unit						1
Number of options granted						64,286
Number of options granted, term						45 days
Number of warrants granted						64,286
Underwriting Agreement [Member] \| Alliance Global Partners Dawson James Securities Inc [Member] \| Class A Units [Member] \| Public Offering [Member]
Percentage of underwriting discount					7.00%
Underwriting discount					$ 1,100
Offering expenses					400
Net proceeds					$ 13,600
Underwriting discount per share (in dollars per share)					$ 2.40
Preferred stock deemed dividend					$ 3,300
Underwriting Agreement [Member] \| Alliance Global Partners Dawson James Securities Inc [Member] \| Class A Units [Member] \| Over-Allotment Option [Member]
Number of shares issued (in shares)					64,000
Net proceeds					$ 6
Underwriting Agreement [Member] \| Alliance Global Partners Dawson James Securities Inc [Member] \| Class B Units [Member]
Sale of stock, price (in dollars per share)						$ 1,000
Number of shares of common stock convertible						28.5714
Exercise price (in dollars per share)						$ 35.00
Issuance of Series A Convertible preferred stock and common stock warrants (in shares)						11,984
Number of warrants to purchase to common stock per unit						28.5714
Number of convertible preferred stock per unit						1
Warrants expiration period						5 years
Conversion price per share						$ 35.00
Underwriting Agreement [Member] \| Class A Unit [Member]
Number of units sold		3,837,000
Sale of stock, price (in dollars per share)		$ 0.57
Underwriting Agreement [Member] \| Class B Unit [Member]
Number of units sold		5,313
Sale of stock, price (in dollars per share)		$ 1,000
Conversion price (in dollars per share)		$ 0.57
Number of shares of common stock convertible		1,754.386
Number of warrants issued		1,754.386
Exercise price (in dollars per share)		$ 0.57
Warrant term		5 years
Underwriting Agreement [Member] \| Series A Convertible Preferred Stock [Member] \| Alliance Global Partners [Member] \| Class B Units [Member]
Number of shares of common stock convertible			515.464
Number of convertible preferred stock per unit			1
Conversion price per share			$ 1.94
Preferred stock deemed dividend			$ 2,500